Activity

05). Conclusion NUSAP1 knockdown can inhibit the proliferation, migration and invasion, and promote the apoptosis of tumor cells through suppressing AKT/mTOR signaling pathway in lung cancer cells.Objective To verify the value of whole genomic copy number variation (WGCNV) detection and scoring system in the diagnosis and prognosis of lung adenocarcinoma. Methods Seventy-six lung adenocarcinoma specimens including ninety-one tumor samples and twenty adjacent non-tumor lung tissue samples were collected using Laser capture microdissection (LCM). Whole genomic amplification (WGA) was used to enrich DNA and construct a sequencing library for next generation sequencing (NGS). Changes of larger than 5Mb CNV in this study were analyzed and scored. The nuclear grading and score of tumor cells in the surgery and pleural effusion cytology of lung adenocarcinoma specimens were evaluated separately. For each case, we evaluated (1) nuclear size, (2) mitotic counts, (3) nuclear atypia, (4) atypical mitoses. The data of disease-free survive (DFS) and overall survive (OS) were collected for assessing the prognostic value of WGCNV score. Meanwhile, receiver operating characteristic (ROC) and area under curve (AUC) werredictive value (NPV) were 99.0% and 90.1%, respectively, the AUC was 0.981. In the differentiation of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) group and invasive adenocarcinoma group, when the cut off value was 1.8, the sensitivity and specificity between the two groups were 78.1% and 94.4%, and the PPV and NPV were 98.0% and 52.0%, respectively, the AUC was 0.896. Conclusion This study verifies that WGCNV scoring system has a potential diagnostic and prognostic value in lung adenocarcinoma.Bone is the second most common metastatic site of renal cell carcinoma (RCC), about 35-40% of metastatic RCC patients are associated with bone metastasis. Bone metastasis can cause pain, pathological fracture, spinal cord compression, hypercalcemia and other skeletal related events (SREs), which may seriously affect patients’ quality of life. RCC patients with bone metastasis, for whom drug therapy alone is less effective and the prognosis is poor, required multi-disciplinary team (MDT) and individualized comprehensive treatment to reduce or delay the onset of SRE, to maintain the quality of life and to extend the time of disease control and survival. In order to update the worldwide treatment progress in RCC with bone metastasis timely, and to improve the standardized diagnosis and treatment of such patients in China, the diagnosis and therapy for bone metastasis of malignant tumor and skeletal-related event expert group formulates “Expert consensus on renal cell carcinoma with bone metastasis (2020 Edition)” .The current situation of pancreatic cancer is that the etiology is not clear and prevention is difficult. The sensitivity and specificity of the auxiliary detection method are low, and early diagnosis is a worldwide problem. The efficacy of existing treatment method is not satisfied and is difficult to break through in a short time. The 5-year overall survival rate is only 7.2%. In face of the current situation of pancreatic cancer, the key solution is to strengthen basic research, explore its etiology and pathogenesis, prevent carcinogenesis and development. Developments of the efficacy of peripheral blood and urine detection technology, imaging diagnosis technology are the critical manners to improve the early diagnosis rate. However, the research on basic and early diagnosis techniques takes a long time and costs a lot, which makes it difficult to achieve result in a short time. Therefore, the problem to be solved urgently is to develop a personalized treatment plan through standardized multi-disciplinary cer in China, summarize successful experience and promote international exchanges, strengthen personnel training and echelon construction, formulate relevant policy and promote the development of MDT in the whole country. This is an expert consensus on the MDT model developed in China, which is not only applied to pancreatic cancer, but also can be used as a reference for other tumors.Stereotactic body radiation therapy (SBRT) has become an important radical approach for early stage non-small cell lung cancer, especially for patients who are inoperable or refuse surgery. Crenolanib research buy In China, this precision radiotherapy technology is being popularized. In order to standardize clinical application, improve the cooperation of technology and scientific research, this expert consensus is established. The consensus includes a brief introduction to the development of SBRT, the physical and technical requirements, the clinical implementation standardization and special clinical problems. The promotion and application of the consensus in clinical practice and constantly updated according to the latest research results will benefit more and more lung cancer patients.Cancer immunotherapy, especially the programmed death 1 (PD-1) and (or) programmed death ligand 1 (PD-L1) checkpoint inhibitors, has ushered in the modern oncology era and has achieved impressive success in the treatment of different tumors, including non-small-cell lung cancer (NSCLC). Yet, only a subset of patients achieved clinical benefit. Therefore, how to effectively screen the potential beneficiaries of PD-1 and (or) PD-L1 inhibitors has become a new challenge in the era of cancer immunotherapy. Clinical studies have shown that the expression level of PD-L1 in NSCLC is positively correlated with the efficacy of PD-1 and (or) PD-L1 inhibitors, and is one of the important predictive biomarkers. However, there are many challenges in PD-L1 testing. With the approving of various PD-1 and (or) PD-L1 inhibitors for immunotherapy setting of NSCLC, expert consensus of important issues regarding clinical significance of PD-L1 testing, testing time-point, as well as the standardization of PD-L1 testing procedure, including the PD-L1 testing operation steps, results’ interpretation, quality control and so on, is of great significance for improving the accuracy of detection and reducing the difference between laboratories. On account to the practical questions of PD-L1 testing, this consensus was finally reached, which is based on the combination of literature, expert experience and internal discussion among committee members, in the hope of providing the guide for standardizing the PD-L1 testing and providing accurate and reliable result to screen the potential patients and predict clinical efficacy. It must be pointed out that in view of the existence of objective and complex factors of PD-L1 testing and the fact that the clinical application of PD-L1 testing is still at the early stage in China, there are still many issues need to be updated in near future based on further practice experience and research data.